Company: MBIO
Filing Date: 2025-12-23
Form Type: 8-K
Source: 0001104659-25-124189
Chunk: 3

Company: MUSTANG BIO, INC.
Filing Date: 2025-12-23
Form: 8-K
Item: Item 8.01
Chunk 3
---
Item 8.01

Other Events

As previously disclosed, Mustang Bio, Inc. (the “Company”) previously entered into that certain License Agreement with Fred Hutchinson Cancer Center (“ Fred Hutch”), dated as of May 17, 2017 (as amended, the “CD20 License Agreement”), under which the Company developed its CD20 CAR-T program. On December 17, 2025, the Company and Fred Hutch entered into a Termination and Release Agreement, pursuant to which: (i) the Company and Fred Hutch agreed to terminate the CD20 License Agreement; (ii) the Company agreed to pay Fred Hutch $730,000 as consideration for extinguishment of approximately $1.4 million in outstanding payables owing to Fred Hutch; and (iii) the parties agreed that, in the event that Fred Hutch, during the three-year period following execution of the Termination and Release Agreement, grants any third party a license under the CD20 patents or other intellectual property that had been licensed to the Company under the CD20 License Agreement, then Fred Hutch will pay to the Company at least 10% of all consideration received by Fred Hutch from such third party under such licensing arrangement (with an additional obligation to negotiate in good faith for a potentially greater percentage share).

Item 9.01 Financial Statements and Exhibits